Alessandro D. Santin, MD

home / authors / alessandro-d-santin-md

Articles

Dr Santin on the Investigation of Sacituzumab Govitecan in Endometrial Cancer

August 30th 2023

Alessandro Santin, MD, discusses the investigation of sacituzumab govitecan in patients with recurrent endometrial carcinoma overexpressing TROP2.

Dr Santin on the Clinical Activity of Sacituzumab Govitecan in Recurrent Endometrial Cancer

Alessandro D. Santin, MD

June 30th 2023

Alessandro Santin, MD, discusses the clinical activity of sacituzumab govitecan-hziy in patients with recurrent endometrial cancer who overexpress Trop-2.

Dr. Santin on Impact of Trastuzumab in Uterine Serous Carcinoma

Alessandro D. Santin, MD

April 24th 2018

Alessandro D. Santin, MD, professor of obstetrics, gynecology, and reproductive sciences at Yale School of Medicine, discusses the impact of trastuzumab (Herceptin) in patients with uterine serous carcinoma.

Dr. Santin on Rationale for Trastuzumab in Uterine Serous Carcinoma

Alessandro D. Santin, MD

March 30th 2018

Alessandro D. Santin, MD, professor of obstetrics, gynecology, and reproductive sciences at Yale School of Medicine, discusses the rationale for trastuzumab (Herceptin) in the treatment of patients with uterine serous carcinoma.